Clinical effect of tacrolimus in the treatment of myasthenia gravis in children
To evaluate the efficacy and safety of tacrolimus in the treatment of children with myasthenia gravis (MG). A total of 28 children with MG were treated with tacrolimus. MG-Activities of Daily Living (MG-ADL) scale was used to assess clinical outcome and safety after 1, 3, 6, 9, and 12 months of trea...
Gespeichert in:
| Veröffentlicht in: | Zhongguo dang dai er ke za zhi 2020-09, Vol.22 (9), p.964 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 964 |
| container_title | Zhongguo dang dai er ke za zhi |
| container_volume | 22 |
| creator | Li, Jiu-Wei Fang, Fang Ren, Xiao-Tun Zhang, Wei-Hua Yang, Xin-Ying Ren, Chang-Hong Gong, Shuai Lyu, Jun-Lan Wang, Xiao-Hui Wang, Xu Wu, Hu-Sheng Ding, Chang-Hong |
| description | To evaluate the efficacy and safety of tacrolimus in the treatment of children with myasthenia gravis (MG).
A total of 28 children with MG were treated with tacrolimus. MG-Activities of Daily Living (MG-ADL) scale was used to assess clinical outcome and safety after 1, 3, 6, 9, and 12 months of treatment.
After tacrolimus treatment, the MG-ADL score at 1, 3, 6, 9 and 12 months was lower than that at baseline (P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2443517947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443517947</sourcerecordid><originalsourceid>FETCH-LOGICAL-p567-1984641757d0d41e7644a8f83eb5ca4b03eb7508092561aa81a9066d0894fca93</originalsourceid><addsrcrecordid>eNo1kMtqwzAURLVoadKkv1C07MYgWe9lMX1BIJvszbV83ajIj0p2IX_fkKarGWYOs5gbsuaM2cJawVbkPucvxpSVTtyRlSidELo0a7KvYhiCh0ix69DPdOzoDD6NMfRLpmGg8xHpnBDmHodL3Z8gn8MhAP1M8BMulD-G2CYctuS2g5jx4aobcnh9OVTvxW7_9lE974pJaVNwZ6WW3CjTslZyNFpKsJ0V2CgPsmFnYxSzzJVKcwDLwTGtW2ad7Dw4sSFPf7NTGr8XzHPdh-wxRhhwXHJdSikUN06aM_p4RZemx7aeUughner_D8QvTNVWTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443517947</pqid></control><display><type>article</type><title>Clinical effect of tacrolimus in the treatment of myasthenia gravis in children</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Li, Jiu-Wei ; Fang, Fang ; Ren, Xiao-Tun ; Zhang, Wei-Hua ; Yang, Xin-Ying ; Ren, Chang-Hong ; Gong, Shuai ; Lyu, Jun-Lan ; Wang, Xiao-Hui ; Wang, Xu ; Wu, Hu-Sheng ; Ding, Chang-Hong</creator><creatorcontrib>Li, Jiu-Wei ; Fang, Fang ; Ren, Xiao-Tun ; Zhang, Wei-Hua ; Yang, Xin-Ying ; Ren, Chang-Hong ; Gong, Shuai ; Lyu, Jun-Lan ; Wang, Xiao-Hui ; Wang, Xu ; Wu, Hu-Sheng ; Ding, Chang-Hong</creatorcontrib><description>To evaluate the efficacy and safety of tacrolimus in the treatment of children with myasthenia gravis (MG).
A total of 28 children with MG were treated with tacrolimus. MG-Activities of Daily Living (MG-ADL) scale was used to assess clinical outcome and safety after 1, 3, 6, 9, and 12 months of treatment.
After tacrolimus treatment, the MG-ADL score at 1, 3, 6, 9 and 12 months was lower than that at baseline (P<0.05), and the MG-ADL score showed a gradually decreasing trend. The response rates to tacrolimus treatment at 1, 3, 6, 9, and 12 months were 59%, 81%, 84%, 88%, and 88% respectively. At 6, 9, 12, and 18 months of treatment, 4, 13, 14, and 15 children respectively were withdrawn from prednisone. No recurrence was observed during treatment. Major adverse reactions/events were asymptomatic reduction in blood magnesium in 5 children and positive urine occult blood in 1 child, which turned negative without special treatment, and tacrolimus was not stopped due to such adverse reactions/events. One child was</description><identifier>ISSN: 1008-8830</identifier><identifier>PMID: 32933627</identifier><language>chi</language><publisher>China</publisher><subject>Activities of Daily Living ; Child ; Humans ; Immunosuppressive Agents ; Myasthenia Gravis - drug therapy ; Neoplasm Recurrence, Local ; Tacrolimus - therapeutic use</subject><ispartof>Zhongguo dang dai er ke za zhi, 2020-09, Vol.22 (9), p.964</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32933627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jiu-Wei</creatorcontrib><creatorcontrib>Fang, Fang</creatorcontrib><creatorcontrib>Ren, Xiao-Tun</creatorcontrib><creatorcontrib>Zhang, Wei-Hua</creatorcontrib><creatorcontrib>Yang, Xin-Ying</creatorcontrib><creatorcontrib>Ren, Chang-Hong</creatorcontrib><creatorcontrib>Gong, Shuai</creatorcontrib><creatorcontrib>Lyu, Jun-Lan</creatorcontrib><creatorcontrib>Wang, Xiao-Hui</creatorcontrib><creatorcontrib>Wang, Xu</creatorcontrib><creatorcontrib>Wu, Hu-Sheng</creatorcontrib><creatorcontrib>Ding, Chang-Hong</creatorcontrib><title>Clinical effect of tacrolimus in the treatment of myasthenia gravis in children</title><title>Zhongguo dang dai er ke za zhi</title><addtitle>Zhongguo Dang Dai Er Ke Za Zhi</addtitle><description>To evaluate the efficacy and safety of tacrolimus in the treatment of children with myasthenia gravis (MG).
A total of 28 children with MG were treated with tacrolimus. MG-Activities of Daily Living (MG-ADL) scale was used to assess clinical outcome and safety after 1, 3, 6, 9, and 12 months of treatment.
After tacrolimus treatment, the MG-ADL score at 1, 3, 6, 9 and 12 months was lower than that at baseline (P<0.05), and the MG-ADL score showed a gradually decreasing trend. The response rates to tacrolimus treatment at 1, 3, 6, 9, and 12 months were 59%, 81%, 84%, 88%, and 88% respectively. At 6, 9, 12, and 18 months of treatment, 4, 13, 14, and 15 children respectively were withdrawn from prednisone. No recurrence was observed during treatment. Major adverse reactions/events were asymptomatic reduction in blood magnesium in 5 children and positive urine occult blood in 1 child, which turned negative without special treatment, and tacrolimus was not stopped due to such adverse reactions/events. One child was</description><subject>Activities of Daily Living</subject><subject>Child</subject><subject>Humans</subject><subject>Immunosuppressive Agents</subject><subject>Myasthenia Gravis - drug therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Tacrolimus - therapeutic use</subject><issn>1008-8830</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtqwzAURLVoadKkv1C07MYgWe9lMX1BIJvszbV83ajIj0p2IX_fkKarGWYOs5gbsuaM2cJawVbkPucvxpSVTtyRlSidELo0a7KvYhiCh0ix69DPdOzoDD6NMfRLpmGg8xHpnBDmHodL3Z8gn8MhAP1M8BMulD-G2CYctuS2g5jx4aobcnh9OVTvxW7_9lE974pJaVNwZ6WW3CjTslZyNFpKsJ0V2CgPsmFnYxSzzJVKcwDLwTGtW2ad7Dw4sSFPf7NTGr8XzHPdh-wxRhhwXHJdSikUN06aM_p4RZemx7aeUughner_D8QvTNVWTw</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Li, Jiu-Wei</creator><creator>Fang, Fang</creator><creator>Ren, Xiao-Tun</creator><creator>Zhang, Wei-Hua</creator><creator>Yang, Xin-Ying</creator><creator>Ren, Chang-Hong</creator><creator>Gong, Shuai</creator><creator>Lyu, Jun-Lan</creator><creator>Wang, Xiao-Hui</creator><creator>Wang, Xu</creator><creator>Wu, Hu-Sheng</creator><creator>Ding, Chang-Hong</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202009</creationdate><title>Clinical effect of tacrolimus in the treatment of myasthenia gravis in children</title><author>Li, Jiu-Wei ; Fang, Fang ; Ren, Xiao-Tun ; Zhang, Wei-Hua ; Yang, Xin-Ying ; Ren, Chang-Hong ; Gong, Shuai ; Lyu, Jun-Lan ; Wang, Xiao-Hui ; Wang, Xu ; Wu, Hu-Sheng ; Ding, Chang-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p567-1984641757d0d41e7644a8f83eb5ca4b03eb7508092561aa81a9066d0894fca93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2020</creationdate><topic>Activities of Daily Living</topic><topic>Child</topic><topic>Humans</topic><topic>Immunosuppressive Agents</topic><topic>Myasthenia Gravis - drug therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Tacrolimus - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Li, Jiu-Wei</creatorcontrib><creatorcontrib>Fang, Fang</creatorcontrib><creatorcontrib>Ren, Xiao-Tun</creatorcontrib><creatorcontrib>Zhang, Wei-Hua</creatorcontrib><creatorcontrib>Yang, Xin-Ying</creatorcontrib><creatorcontrib>Ren, Chang-Hong</creatorcontrib><creatorcontrib>Gong, Shuai</creatorcontrib><creatorcontrib>Lyu, Jun-Lan</creatorcontrib><creatorcontrib>Wang, Xiao-Hui</creatorcontrib><creatorcontrib>Wang, Xu</creatorcontrib><creatorcontrib>Wu, Hu-Sheng</creatorcontrib><creatorcontrib>Ding, Chang-Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhongguo dang dai er ke za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jiu-Wei</au><au>Fang, Fang</au><au>Ren, Xiao-Tun</au><au>Zhang, Wei-Hua</au><au>Yang, Xin-Ying</au><au>Ren, Chang-Hong</au><au>Gong, Shuai</au><au>Lyu, Jun-Lan</au><au>Wang, Xiao-Hui</au><au>Wang, Xu</au><au>Wu, Hu-Sheng</au><au>Ding, Chang-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical effect of tacrolimus in the treatment of myasthenia gravis in children</atitle><jtitle>Zhongguo dang dai er ke za zhi</jtitle><addtitle>Zhongguo Dang Dai Er Ke Za Zhi</addtitle><date>2020-09</date><risdate>2020</risdate><volume>22</volume><issue>9</issue><spage>964</spage><pages>964-</pages><issn>1008-8830</issn><abstract>To evaluate the efficacy and safety of tacrolimus in the treatment of children with myasthenia gravis (MG).
A total of 28 children with MG were treated with tacrolimus. MG-Activities of Daily Living (MG-ADL) scale was used to assess clinical outcome and safety after 1, 3, 6, 9, and 12 months of treatment.
After tacrolimus treatment, the MG-ADL score at 1, 3, 6, 9 and 12 months was lower than that at baseline (P<0.05), and the MG-ADL score showed a gradually decreasing trend. The response rates to tacrolimus treatment at 1, 3, 6, 9, and 12 months were 59%, 81%, 84%, 88%, and 88% respectively. At 6, 9, 12, and 18 months of treatment, 4, 13, 14, and 15 children respectively were withdrawn from prednisone. No recurrence was observed during treatment. Major adverse reactions/events were asymptomatic reduction in blood magnesium in 5 children and positive urine occult blood in 1 child, which turned negative without special treatment, and tacrolimus was not stopped due to such adverse reactions/events. One child was</abstract><cop>China</cop><pmid>32933627</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1008-8830 |
| ispartof | Zhongguo dang dai er ke za zhi, 2020-09, Vol.22 (9), p.964 |
| issn | 1008-8830 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2443517947 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Activities of Daily Living Child Humans Immunosuppressive Agents Myasthenia Gravis - drug therapy Neoplasm Recurrence, Local Tacrolimus - therapeutic use |
| title | Clinical effect of tacrolimus in the treatment of myasthenia gravis in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A55%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20effect%20of%20tacrolimus%20in%20the%20treatment%20of%20myasthenia%20gravis%20in%20children&rft.jtitle=Zhongguo%20dang%20dai%20er%20ke%20za%20zhi&rft.au=Li,%20Jiu-Wei&rft.date=2020-09&rft.volume=22&rft.issue=9&rft.spage=964&rft.pages=964-&rft.issn=1008-8830&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2443517947%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443517947&rft_id=info:pmid/32933627&rfr_iscdi=true |